Approved inhalation products incorporating Skyepharma technologies

flutiform® is a fixed-dose combination of the commonly prescribed corticosteroid fluticasone propionate and the fast-onset long-acting b2 adrenergic agonist formoterol fumarate dihydrate in a pressurised Metered Dose Inhaler (pMDI), that was developed by Skyepharma. It is approved for sale in many European countries and in Japan.

Flutiform which was developed by Skyepharma from original concept to regulatory approval

Partners: Mundipharma, Kyorin

Skyepharma identified a key opportunity in the treatment of asthma by combining two established drugs. We then used our inhalation expertise and proprietary technology to create the product in a novel MDI. We took the product from initial concept through the development process to commercial manufacture. 

It has been partnered with pharmaceutical companies for commercialisation in most markets, and was first launched in Europe in September 2012 and in Japan in November 2013.

> Find out more about how we developed the product
> Find out more about our partners
> Find out more about flutiform® licensing opportunities

Other approved inhalation products

Paxil DR (paroxetine) incorporates Skyepharma's Geomatrix technology

Partner: GlaxoSmithKline (GSK)

Skyepharma’s technologies have been incorporated into a number of products developed by GlaxoSmithKline as follows.

Inhalation Product

Primary Indication 

Licensee / Partner

RELVAR™ ELLIPTA™ (Europe/Japan)

Asthma / COPD








* Approved in some countries 
** Approved and launched in US 

Contact us to find out how we can help with your inhalation development.

Copyright 2014, Skyepharma. All Rights Reserved. Skyepharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 46-48 Grosvenor Gardens, London SW1W 0EB, United Kingdom

Contact addresses

Skyepharma PLC
46-48 Grosvenor Gardens

Tel: +44 207 881 0524

Fax: +44 207 881 1199

E-mail us

Skyepharma AG
Eptingerstrasse 61
4132 Muttenz

Tel: +41 61 467 5555

Fax: +41 61 467 5500

E-mail us

This website works best using cookies.